Literature DB >> 24617790

Percutaneous neuromodulation of the posterior tibial nerve for the treatment of faecal incontinence - mid-term results: is retreatment required?

F de la Portilla1, M Laporte, M V Maestre, J M Díaz-Pavón, J L Gollonet, C Palacios, J M Vázquez-Monchul, A M García-Cabrera, R M Jiménez-Rodríguez, J M Sánchez Gil.   

Abstract

AIM: Posterior tibial nerve stimulation (PTNS) has emerged in recent years as a therapy for faecal incontinence. Its long-term effectiveness is yet to be established, along with what the form of retreatment should be in the event of loss of effectiveness. The present study aimed to establish the mid-term results to identify the proportion of patients who may need further treatment, and if so when.
METHOD: A prospective study including 30 patients was conducted at an academic hospital. The patients underwent 12 weekly outpatient treatment sessions, each lasting 30 min (first PTNS phase). Neuromodulation was discontinued in those patients who did not have a 40% decrease in their pretreatment Wexner score. Patients having a better than 40% response were offered another 12-week course of complete treatment (second PTNS phase), following which they received no further PTNS treatment (phase without PTNS) but were assessed at 6 months and 2 years.
RESULTS: All patients finished the first phase and 22/30 patients continued to the second phase. During this phase 11 patients showed an improved Wexner score (baseline/first phase/second phase: 14.3 ± 4.2 vs 9.9 ± 5.4 vs 6.8 ± 5.4). After a 6-month period without any treatment, the score was still improved in 11/30 patients (9.1 ± 6.2). At 2 years there was improvement in 16/30 patients (8.8 ± 7.1). There was a significant improvement in three variables of the quality of life questionnaire: lifestyle, coping behaviour and embarrassment.
CONCLUSION: The response to first and second phase PTNS was maintained for up to 2 years. Retreatment was not required in about half of patients, even when they had finished the treatment 6 months or 2 years previously. Colorectal Disease
© 2013 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Keywords:  Neuromodulation; faecal incontinence; treatment

Mesh:

Year:  2014        PMID: 24617790     DOI: 10.1111/codi.12539

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  5 in total

1.  Evaluation of the anorectal motor response after percutaneous stimulation of the posterior tibial nerve in patients with fecal incontinence.

Authors:  R Rodríguez Carrillo; M D Ruiz Carmona; R Alós Company; A Frangi Caregnato; M Alarcón Iranzo; A Solana Bueno; R Lozoya Trujillo; E García-Granero Ximénez
Journal:  Tech Coloproctol       Date:  2019-09-19       Impact factor: 3.781

2.  Efficacy of Bilateral Transcutaneous Posterior Tibial Nerve Stimulation for Fecal Incontinence.

Authors:  Georgia Dedemadi; Shota Takano
Journal:  Perm J       Date:  2018

3.  Long-term efficacy of percutaneous tibial nerve stimulation for faecal incontinence and a new approach for partial responders.

Authors:  M Bosch-Ramírez; L Sánchez-Guillén; M J Alcaide-Quirós; M M Aguilar-Martínez; M Bellón-López; A López Delgado; F López-Rodríguez-Arias; A Muñoz-Duyos; X Barber-Valles; A Arroyo
Journal:  Tech Coloproctol       Date:  2022-10-12       Impact factor: 3.699

4.  A pilot study assessing the efficacy of posterior tibial nerve stimulation in the treatment of low anterior resection syndrome.

Authors:  V Vigorita; S Rausei; P Troncoso Pereira; I Trostchansky; A Ruano Poblador; E Moncada Iribarren; C Facal Alvarez; A de San Ildefonso Pereira; E Casal Núñez
Journal:  Tech Coloproctol       Date:  2017-04-24       Impact factor: 3.781

5.  Short-term outcome of percutaneous posterior tibial nerve stimulation (PTNS) for the treatment of faecal incontinence.

Authors:  E Peña Ros; P A Parra Baños; J A Benavides Buleje; J M Muñoz Camarena; C Escamilla Segade; M F Candel Arenas; F M Gonzalez Valverde; A Albarracín Marín-Blázquez
Journal:  Tech Coloproctol       Date:  2016-01       Impact factor: 3.781

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.